Oxford Immunotec slams Qiagen, Quest with patent suits; Burning Rock scores $23M for cancer tests;

> Oxford Immunotec is suing diagnostic heavyweights Qiagen ($QGEN), Quest Diagnostics ($DGX) and LabCorp ($LH) for infringing patents for its TB test. Story (reg. req.)

> MDxHealth unveiled positive data for its bladder cancer liquid biopsy tool, showing the test had a negative predictive value of 98.3% in a group of 154 patients. Statement

> BioTime's ($BTX) OncoCyte subsidiary is teaming up with The Wistar Institute to develop a noninvasive, blood-based test for the early detection of lung cancer. More

> China's Burning Rock Biotech roped in $23 million to develop its solid tumor cancer tests. Story

> CombiMatrix ($CBMX) scored approval from the New York State Department of Health to market its prenatal diagnosis test in the state. Statement

And Finally… The U.K.'s NHS approved cancer-sniffing dogs for a prostate cancer trial after a study found that the animals could detect prostate tumors in urine in 93% of cases. Story